{"id":"ana598","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ANA598 works by binding to the NS5B polymerase, which is essential for the replication of the hepatitis C virus. This binding prevents the virus from replicating, thereby reducing the viral load in the body.","oneSentence":"ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:15.787Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT00978497","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-09","conditions":"HCV Infection","enrollment":97},{"nctId":"NCT01903954","phase":"PHASE2","title":"A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Hepatitis C, Chronic","enrollment":283},{"nctId":"NCT01714154","phase":"PHASE1","title":"A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT01612143","phase":"PHASE1","title":"A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06","conditions":"Healthy Volunteer","enrollment":40},{"nctId":"NCT00782353","phase":"PHASE1","title":"Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ANA598","genericName":"ANA598","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus. Used for Chronic hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}